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Abstract: The isolation and characterization from the sand fly Phlebotomus perniciosus of a
Wickerhamomyces anomalus yeast strain (Wa1F1) displaying the killer phenotype was recently reported.
In the present work, the killer toxin (KT) produced by Wa1F1 was purified and characterized, and
its antimicrobial activity in vitro was investigated against fluconazole- susceptible and -resistant
clinical isolates and laboratory strains of Candida albicans and C. glabrata displaying known mutations.
Wa1F1-KT showed a differential killing ability against different mutant strains of the same species.
The results may be useful for the design of therapeutic molecules based on Wa1F1-KT and the study
of yeast resistance mechanisms.
Keywords: Wickerhamomyces anomalus; yeast killer toxin; Candida albicans; Candida glabrata;
antifungal resistance
Key Contribution: A novel killer toxin produced by the recently isolated Wickerhamomyces anomalus
strain 1F1 showed a differential killing ability against fluconazole-susceptible and -resistant Candida
clinical isolates and laboratory strains displaying known mutations.
1. Introduction
Yeast strains belonging to diverse species produce and secrete proteins or glycoproteins, known as
killer toxins (KTs), that are lethal to susceptible strains [1,2]. This property, which offers a competitive
advantage to self-immune killer yeasts in their ecological niches, has found several applications
in the biological control of plant pathogens and spoiling yeasts in the food and fermentation
industries [3]. In the medical field, KTs have been used for the biotyping of pathogenic microorganisms,
in epidemiological studies, and for the identification of novel cellular targets in microbial cells and the
development of new antimicrobials [4–6].
Some KTs, such as K1 and K28 from Saccharomyces cerevisiae, have a narrow spectrum of activity,
limited to susceptible strains of the same species, while other KTs show a wide killing spectrum [2].
In particular, some Wickerhamomyces anomalus (formerly Pichia anomala) KTs proved to be active against
a wide range of microorganisms, including other yeast species, filamentous fungi, bacteria, and
protozoan parasites [2,7,8].
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Killer strains of W. anomalus have been isolated from different sources, including plants and food
products [9–11], arthropods such as the crab Portunus trituberculatus [12], and mosquitoes of the species
Anopheles stephensi [13,14]. Recently, the isolation and characterization of a W. anomalus strain displaying
the killer phenotype was reported from specimens of the sand fly Phlebotomus perniciosus [15].
The ability to inhibit harmful microorganisms in a variety of habitats and the wide killing spectrum
of the produced KTs have prompted the use of W. anomalus as a bio-control agent [7,16], since it
could be classed as a low risk microorganism, rarely traced in human samples [17,18]. In addition,
W. anomalus KTs activity against dermatophytes and pathogenic yeasts, especially Candida spp., led to
the hypothesis that could be applied in medical mycology as alternative antifungal compounds [19–21].
Candida spp. are the most frequently isolated yeasts in clinical specimens. The frequency of
invasive opportunistic fungal infections caused by species of this genus has significantly increased
in recent years, particularly in immunosuppressed individuals and patients with indwelling medical
devices [22]. Worldwide, the prevalent cause of invasive candidiasis remains C. albicans, although
the epidemiology of candidal infections has gradually shifted towards non-albicans species, such as
C. glabrata and C. krusei [22–24]. Increasing concern is rising in view of growing reports of resistance to
antifungal drugs, with particular reference to resistance to azoles in non-albicans Candida species [25,26].
In the aim of searching for new molecules, potentially effective against strains resistant to
conventional antifungal drugs, we investigated the in vitro activity of a KT produced by the recently
isolated W. anomalus strain 1F1 (Wa1F1-KT) [15] against both susceptible and azole-resistant clinical
isolates as well as laboratory strains of C. albicans and C. glabrata displaying known mutations [27–31].
2. Results
2.1. Wa1F1-KT Production
The production of Wa1F1-KT by the strain W. anomalus 1F1 was analyzed over time. The activity
of the concentrated culture supernatant obtained at different time periods was determined against the
reference C. lusitaniae strain on solid medium and quantified by Arbitrary Units/mL (1 Arbitrary Unit
(AU) is defined as the amount of KT producing an inhibition zone of 1 mm2). As shown in Figure 1,
the results indicate that the activity of the Wa1F1-KT sample obtained after 24 h of incubation was low
(559 AU/mL), although it increased after 48 h of incubation (1815 AU/mL), and reached a maximum
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for th ir activity against the reference Candida lusitaniae strain grown on solid medium. Arbitrary Unit
(AU): mou t of KT which pr duces an inhibition zone of 1 mm2.
2.2. Western Blot Analysis of Wa1F1-KT
Western blot analysis was carried out on crude extracts from 72-h cultures of the W. anomalus
strains 1F1 and ATCC 96603 (KT-producing, positive control strain). As a negative control, a crude
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extract from W. anomalus UM3 (KT-nonproducing strain) culture and 50-fold concentrated YPD medium
were used. Bands were detected with mAbKT4, a monoclonal antibody directed against a KT produced
by the reference ATCC 96603 strain (Wa96603-KT) and shown to cross-react with KTs produced by
other W. anomalus strains and other killer yeasts [14,32,33]. The results showed that mAbKT4 reacts
with high-molecular mass proteins in samples obtained from W. anomalus 1F1 and ATCC 96603, but not
from controls (Figure 2). A single band of approximately 220 kDa was revealed in extracts from the
reference strain, while a single band with a lower molecular mass (approximately 160–170 kDa) was
detected in the extract from 1F1 strain, indicating the secretion of KTs with a common epitope, although
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Figure 2. estern blot analysis using mAbKT4 to probe 50-fold concentrated crude extracts of
(1) Wickerhamomyces anomalus ATCC 96603, 2 µL; (2) W. anomalus ATCC 96603, 5 µL; (3) W. anomalus
UM3, 5 µL; (4) YPD medium, 5 µL; (5) W. anomalus 1F1, 5 µL. Molecular masses (kDa) are shown on
the left.
2.3. Characterization of Wa1F1-KT Using Size Exclusion Chromatography
The concentrated extract from W. anomalus 1F1 culture was analyzed by size exclusion
chromatography and eluted fractions were assayed for killing activity against the reference C. lusitaniae
strain. In agreement with the immunoblot data, the results indicated the elution of active Wa1F1-KT in
fractions 34–39 of the size exclusion chromatogram (Figure 3), corresponding to the highest molecular
mass separation zone.
2.4. Activity of Wa1F1-KT
Wa1F1-KT was tested by an agar diffusion assay ag inst the reference C. lusitaniae NEQAS
6208 strain and clinical isolates an laboratory strains of C. albicans and C. glabrata susceptible or
resistant to fl conazole. The results showed that, when tested at 25 ◦C, Wa1F1-KT was active
towards both fluc nazole-susceptible and -resistant strains of C. glabrata, with some quantitative
differences (Table 1). Wa1F1-KT showed no effect gainst the reference C. albicans SC5314 strain and
against two fluconazole-susceptible clinical isolates (DSY347 nd DSY544) and the DSY544-derived
fluconazole-resistant m tant strain (DSY775) of C. albicans. On the contrary, a good effect was detected
against the DSY347-derived fluconazole-resistant mutant C. albicans DSY289 strain. No effect against
any of the tested strains was detected when the assay was carried out at 30 and 37 ◦C.
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Table 1. Sensitivity of laboratory strains and clinical isolates of Candida spp. susceptible or resistant to
fluconazole against killer toxin Wa1F1-KT.
Strain Features and Genotype Wa1F1-KT Sensitivity(mm Growth Inhibition) a
C. albicans SC5314 Reference laboratory strain, FluS 0
C. albicans DSY347 FluS clinical strain [27] 0
C. albicans DSY289 FluR, DSY347 ERG11: S405F, Y132H; TAC1: A736V [27,29] 14
C. albicans DSY544 FluS clinical strain [30] 0
C. albicans DSY775 FluR, DSY544 ERG11: G464S, TAC1: G980W [30] 0
C. glabrata DSY562 FluS clinical strain [28] 13
C. glabrata DSY565 FluR clinical strain [28] 12
C. glabrata SFY93 FluR, DSY562 pdr1∆ [31] 12
C. glabrata SFY105 FluR, DSY562 pdr1∆-T588A [31] 13
C. glabrata SFY115 FluR, DSY562 pdr1∆-L280F [31] 13
C. glabrata SFY116 FluR, DSY562 pdr1∆-P822L [31] 13
C. lusitaniae NEQAS6208 Reference laboratory strain, FluS 17
a Diameter (mm) of growth inhibition zone, mean values (±1 mm) from four independent experiments.
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Figure 3. Wickerhamomyces anomalus 1F1 crude extract separation on HiPrep Sephacryl S-200 column.
Partial chromatographic traces, displaying the active fractions (34–39), as determined by killing
assay on Candida lusitaniae NEQAS 6208. Continuous and dashed lines refer to absorbance values
(milli Absorbance Units, mAU) at 280 nm (mainly Trp absorbance) and 215 nm (peptide bond
absorbance), respectively. Inset: complete chromatogram traces. The arrows indicate the elution
peak of active fractions.
2.5. Exo-β-1,3-Glucanase Activity
To investigate if Wa1F1-KT could act on susceptible yeast strains by hydrolyzing major cell wall
components, its ability to digest the soluble β-1,3-glucan laminarin was assayed in comparison with
Wa96603-KT, the KT produced by the Williopsis saturnus var. mrakii MUCL 41968 (Wm41968-KT),
with known β-glucanase activity [34], and laminarinase. The results showed that all KTs could
hydrolyze laminarin to an end product presenting similar relative mobility to the product of the
laminarinase reaction (Figure 4).
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strains  tested  in  this  study, while Wa96603‐KT was previously  shown  to kill different  clinical C. 
albicans isolates [43,44]. Selective killing of non‐albicans species by W. anomalus KTs with β‐glucanase 
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Figure 4. Thin-layer chromatogram of hydrolysis products of laminarin by crude killer toxins (KTs).
Before loading, laminarin was incubated for 2 (left panel) or 4 (right panel) hours at 25 ◦C with:
(1) heat-inactivated Wa1F1-KT; (2) Wa1F1-KT; (3) heat-inactivated laminarinase; (4) laminarinase;
(5) heat-inactivated Wa96603-KT; (6) Wa96603-KT; (7) heat-inactivated Wm41968-KT; (8) Wm41968-KT.
3. Discussion
Mucosal and invasive candidiasis are the most common mycoses in humans [22–24,35,36].
Invasive candidiasis and candidemia, in particular, are an emerging health problem, especially in
hospitalized and immunosuppressed individuals and patients with indwelling medical devices [22].
Additionally, the diffusion of antifungal drugs resistance in Candida spp., particularly non-albicans,
makes it necessary to look for new treatments against these infections [37].
In the present study, with the aim of searching for alternative antifungal agents, a KT produced
by the newly isolated W. anomalus 1F1 strain [15] was assayed in vitro against clinical isolates and
laboratory strains of C. albicans and C. glabrata displaying known mutations and different susceptibility
to fluconazole [27–31].
KTs produced by strains of W. anomalus have previously shown to be active against Candida spp.
both in vitro and in vivo [20,21,38,39], although little is known on their activity against resistant strains.
W. anomalus may produce different KTs with variable molecular mass (8–300 kDa), structural
characteristics, pH and temperature optima, and antimicrobial activity range [7,40]. KTs from
W. anomalus and other killer yeasts have been shown to exert a β-1,3-glucanase activity, and may cause
damage to the cell wall of susceptible yeasts as a result of degradation of the main β-glucans cell wall
components [20,34,41,42].
Our results showed that Wa1F1-KT shares at least one epitope with the KT produced by
W. anomalus ATCC 96603, although the molecular mass of the two toxins is slightly different, indicating
that they are related but not identical. Both Wa96603-KT and Wa1F1-KT degraded the soluble β-glucan
laminarin in a manner similar to laminarinase, an endo-1,3(4)-β-glucanase, as did Wm41968-KT,
whose glucanase activity had been already suggested [34].
The spectrum of activity of Wa96603-KT and Wa1F1-KT, however, appeared to be different, as the
latter proved to be active against the C. glabrata isolates but did not affect the majority of C. albicans
strains tested in this study, while Wa96603-KT was previously shown to kill different clinical C. albicans
isolates [43,44]. Selective killing of non-albicans species by W. anomalus KTs with β-glucanase activity
has previously been reported [20]. This differential spectrum may be explained with differences in the
specificity of β-glucanase activity of KTs, which may selectively recognize different glycosidic linkages
and glucan receptors on target yeast cells [45,46].
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Although some KTs from W. anomalus display high stability at 37 ◦C and even higher
temperatures [47], many KTs show lower thermostability [7]. We found that the optimal temperature
for Wa1F1-KT activity was lower than the physiological value in the human body. Nevertheless,
the absence of β-glucans on mammalian cells suggests its potential application against fungal
infections at skin and mucosal membrane levels, as has been demonstrated with other KTs [48].
Further characterization of Wa1F1-KT enzymatic activity and the cloning of its encoding gene may
represent the next step to investigate the feasibility to produce molecules with broader therapeutic
activity, possibly including systemic infections.
The mechanism of action of Wa1F1-KT on C. glabrata appeared to be independent from
the fluconazole-resistance pathway, as only slightly different effects were observed against the
susceptible clinical isolate (DSY562) or its mutant derivative strains (SFY93, SFY105, SFY115, SFY116).
This phenomenon underlies the potential of Wa1F1-KT as a universally active anti-C. glabrata tool,
likely not affected by drug-resistance phenotypes.
On the contrary, the fact that Wa1F1-KT was active only on C. albicans DSY289 implies that the
mechanism of action of the toxin may be dependent upon the specific mutations that confer resistance
to fluconazole in this strain. C. albicans DSY289 was derived from the fluconazole-susceptible clinical
strain DSY347 by mutations that confer combined resistance to azoles [27,29]. In particular, the point
mutations S405F/Y132H in the ERG11 gene encoding the enzyme lanosterol 14-α-sterol demethylase,
which is involved in converting lanosterol into ergosterol, an essential component of the fungal cell
membrane, are associated with a conformational change of the target enzyme and reduced interaction
or binding of azoles [49–51]. The gain-of-function A736V mutation in the transcriptional activator
TAC1 causes the overexpression of the ATP binding cassette (ABC)-transporters CDR1 and CDR2,
decreasing the concentration of azoles within the fungal cell [29,52]. It is not clear how this mutation
may affect Wa1F1-KT activity, but it may be speculated that the overexpression of transport systems
and associated extracellular loops could possibly alter the recognition of the cell surface target by
the toxin or that the transcriptional activator TAC1 is involved in the regulation of transcription of
toxin receptors.
Further studies aimed at the biochemical characterization of properly purified Wa1F1-KT,
the elucidation of its mechanism of action, and the reasons for its differential killing ability against
different mutant strains can provide important information for developing new strategies to combat
infections caused by azole-resistant Candida strains.
4. Materials and Methods
4.1. Yeast Strains
Strains belonging to the species W. anomalus, W. saturnus var. mrakii, C. lusitaniae, C. albicans,
and C. glabrata were used in this study. W. anomalus 1F1 isolated from P. perniciosus [15], W. anomalus
ATCC 96603 (a KT-producing strain formerly referred to as UP25F) [32], and Williopsis saturnus var.
mrakii MUCL 41968 [34] were used for the production of Wa1F1-KT, Wa96603-KT, and Wm41986-KT,
respectively. The KT non-producing, KT-susceptible, W. anomalus UM3 strain was also used in this
study as a negative control for KT expression [32].
The activity of Wa1F1-KT was tested against the reference C. albicans strain SC5314, two wild-type
C. albicans clinical isolates (DSY544 and DSY347) [27,30], two C. albicans mutant strains resistant
to fluconazole (DSY775, derived from DSY544, and DSY289, derived from DSY347) [27,29,30], two
wild-type C. glabrata clinical isolates susceptible (DSY562) and resistant (DSY565) to fluconazole [28],
and four C. glabrata fluconazole-resistant strains derived from DSY562 by mutations in the gene
CgPDR1 (SFY93, SFY105, SFY115, SFY116) [31]. The reference strain C. lusitaniae NEQAS 6208, known
to be susceptible to the activity of Wa1F1-KT [15], was also used as a positive control for KT activity.
Yeasts maintained in sterile distilled water were subcultured on Sabouraud Dextrose Agar plates.
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4.2. Media
KT-producing strains were grown in YPD medium (1% yeast extract, 2% peptone, and 2% dextrose),
then subcultured for KT production in YPD medium with 15% glycerol, buffered at pH 4.6 with 0.1 M
citric acid and 0.2 M Na2HPO4. For the KT activity assay, YPD medium was added with 3% agar,
and 0.003% methylene blue, and adjusted to pH 4.6 with 0.1 M citric acid and 0.2 M Na2HPO4.
4.3. Production of KTs
For the production of crude extracts, a seed culture of the W. anomalus and W. saturnus var. mrakii
strains was incubated at 20 ◦C for 24 h with shaking at 150 rpm in YPD medium. Flasks (500-mL
volume) containing 100 mL of YPD buffered at pH 4.6, with 15% glycerol, were inoculated with
1 mL of the seed culture and incubated at 20 ◦C for 72 h with shaking (150 rpm). After this period,
the cells were removed by centrifugation (5000× g, 10 min, 4 ◦C); the supernatant was filtered through
0.45 µm pore size membranes (Merck Millipore, Darmstadt, Germany) and concentrated (50-fold)
through an Amicon Ultra-15 (10-kDa cutoff) filter unit (Merck Millipore) by centrifugation at 4000× g,
4 ◦C. Accordingly, a concentrated extract of YPD medium used for KT production was prepared.
The concentrated crude extracts were stored at 4 ◦C until use.
4.4. Western Blot Analysis
The crude extracts from W. anomalus ATCC 96603, UM3, and 1F1 were analyzed by
non-continuous denaturing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE)
in 7% polyacrylamide gel, at 100 Volts for 2 h in a minigel system (Bio-Rad Laboratories, Hercules, CA,
USA). Concentrated YPD medium was also run as a control.
Proteins were electrically transferred to a polyvinylidene difluoride (PVDF) membrane at 100 Volts
for 1 h. The total protein content of the crude extracts was estimated by Ponceau staining prior to
immunodetection. The PVDF membrane was then incubated for 1 h at room temperature with 5%
bovine serum albumin in Tris-buffered saline (TBS) at pH 7.5 and 0.5% tween-20 (TBS-T). Subsequently,
the membrane was incubated overnight at 4 ◦C with a 1:500 dilution in TBS-T of the monoclonal
W. anomalus ATCC 96603 KT-neutralizing antibody mAbKT4 [32], known to cross-react with KTs
from other Wickerhamomyces [14] and Williopsis [33] strains. After washing three times in TBS-T,
the membrane was incubated for 1 h at room temperature with a secondary, peroxidase-conjugated
anti-mouse antibody. The membrane was thoroughly washed with TBS-T, incubated for 1 min with the
proper substrate (BM Chemiluminescence blotting substrate, Roche, Basel, Switzerland), and detected
by ChemiDoc 2000R (Kodak, Rochester, NY, USA).
4.5. Characterization of Wa1F1-KT Using Size Exclusion Chromatography
The crude Wa1F1-KT was dialyzed against 0.01 M citric acid-Na2HPO4 buffer (pH 4.5) for 24 h
at 4 ◦C using a membrane with a molecular mass cut-off of 10 kDa. Analytical gel filtration was
performed on a HiPrep Sephacryl S-200 prepacked column (GE Healthcare Life Sciences, Marlborough,
MA, USA), characterized by bed dimensions of 16 × 600 mm and an exclusion limit (for globular
proteins) of about 400 kDa, connected to an AKTA purifier system (GE Healthcare Life Sciences).
Dialyzed crude extract was applied to the column, equilibrated, and eluted with 1.2 column volume of
citric acid-Na2HPO4 buffer, pH 4.5. Eluted fractions (1 mL) were combined according to chromatogram
peaks, lyophilized, and re-solubilized in 1 mL of sterile distilled water. Total protein content was
quantified with an infrared-based spectrometry system (Direct Detect™, Merck Millipore) and the
concentrated fractions were assayed for killing activity against the C. lusitaniae NEQAS 6208 susceptible
strain (see below).
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4.6. Evaluation of Wa1F1-KT Activity
The activity of Wa1F1-KT was tested against the reference C. lusitaniae NEQAS 6208 strain and
fluconazole-susceptible or -resistant clinical isolates as well as laboratory strains of C. albicans and
C. glabrata. Each test strain, grown overnight on SDA plates, was resuspended in water to a final
concentration of 0.5 McFarland and spread (100 µL) on the surface of YPD agar plates. Crude extracts
from W. anomalus 1F1 were poured into wells of 8 mm (40 µL per well) cut into the agar plates.
The plates were incubated for 48 h at 25, 30, or 37 ◦C and the diameter of the area of growth inhibition
was measured.
4.7. Laminarin Hydrolysis
The ability of Wa1F1-KT to hydrolyze the soluble β-1,3-glucan laminarin (Sigma-Aldrich, St. Louis,
MO, USA) was assayed in comparison to Wa96603-KT, Wm41968-KT (with recognized β-glucanase
activity [34]), and laminarinase (Sigma-Aldrich). The reaction mixtures contained 20 µL of 50-fold
concentrated crude KTs or 10 µL of laminarinase (4.5 U/mL) and 2 mg/mL laminarin in 100 µL of
citric acid-Na2HPO4 buffer (0.01 M, pH 4.5). After incubation at 25 ◦C for 2 and 4 h, the reaction was
stopped by heating at 100 ◦C for 15 min. The activity on laminarin was estimated through observation
of the end products of laminarin hydrolysis by thin layer chromatography [53]. Reaction mixtures
containing crude KTs inactivated by heating at 100 ◦C for 15 min were used as controls.
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